Comparative Pharmacology
Head-to-head clinical analysis: CAPRELSA versus SUNITINIB MALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPRELSA versus SUNITINIB MALATE.
CAPRELSA vs SUNITINIB MALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and oncogenesis, including VEGFR2, EGFR, and RET.
Sunitinib is a multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase 3 (FLT3), colony-stimulating factor receptor type 1 (CSF-1R), and glial cell line-derived neurotrophic factor receptor (RET). It exerts antiangiogenic and antitumor activity by blocking signaling pathways involved in tumor growth and angiogenesis.
300 mg orally once daily, with or without food.
50 mg orally once daily for 4 weeks, followed by 2 weeks off (4/2 schedule). Alternatively, 37.5 mg orally once daily on a continuous daily dosing schedule for gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor failure.
None Documented
None Documented
Terminal half-life approximately 90 hours (range 30–150 hours), supporting once-daily dosing; steady-state achieved by day 15.
40-60 hours for sunitinib; 80-110 hours for active metabolite SU12662. Clinical context: supports once-daily dosing with 2 weeks on/1 week off schedule.
Primarily fecal (approximately 75% of administered dose, mainly as unchanged drug and metabolites); renal excretion accounts for about 25% (less than 1% unchanged).
Fecal (61%), renal (16%) as unchanged drug and metabolites.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor